🙌BRAND NEW 🙌
Explore the future of HPB surgical education with the E-AHPBA Online Academy — expert-led webinars, interactive modules & global collaboration to advance your practice.
Read more - https://t.co/iG7yqvatZJ
🧬 RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer
🎯 A milestone one in @Nature 🎯
🦠 Responders with vaccine induced t-cells have prolonged RFS compared to non responders
💉 Vaccine for PDAC not a dream anymore?!
https://t.co/yXsOhtqBwj
Antibiotics 💊 for prophylaxis during pancreatoduodenectomy 🙋🏻♀️ … did you change your practice?
💉 Pip/Tazobactam ⬇️ surgical site infections and major complications
New meta-analysis supporting 🇺🇸 trials just published!
👉https://t.co/n13OXzk5PB
First paper from Novara @UniAvogadro
Data from #MANCTRA-1 highlight the relevance of
➡ Socioeconomic inequity by HDI (local factors)
➡ Adherence to clinical guidelines (local protocol)
on
🔥 Clinical outcomes
Massive 🙏to promoters & collaborators!
https://t.co/SHq61Vssmu
💫 Building the next gen of HPB Surgeons ✨
Read about the new @EAHPBA programs
👩🎓 Early Career Group
🖥️ Online Academy
🧙♂️ Mentorship Program and... fellowships!
The future is (finally) already here!
👉https://t.co/cjBoeS0Kpq
Tribute to Claudio Bassi by our chairman @SalviaRobi at the @IHPBA meeting in Cape Town. Claudio truly believed in young generations and created a training system for pancreatic surgery that is still unique natuonwide. We prouldy carry your legacy on ❤️😷 @EAHPBA@AHPBA@APHPBA
🚨PANDORINA, a binational 🇳🇱🇮🇹RCT of drain 🆚 no drain in distal pancreatectomy out in @LancetGastroHep !
✅Major morbidity 20% vs 15%
✅POPF 27% vs 12%
➡️A no-drain policy is safe and reduced POPF and should be the new standard approach
@DPCG_official https://t.co/Y5Wu8wahDY
📣 Check out our latest review article published in @jogs, focusing on state-of-the-art in simultaneous resection for colorectal cancer with synchronous liver metastases
➡️ https://t.co/K2iLYEpj4l
@timpawlik@MarcDiMartino@FPrimavesi@DTsilimigras@Adam_Frampton1
Out now! How many patients fail to access adjuvant therapy after surgery for resectable #PancreaticCancer?25%🥧! Why?(Data from 317 pts)
1) 🩹Postop compl
2) 🧑⚕️Oncologist's choice
3) 💊Comorbidities
Less likely:
- 👵Elderly
- 💧POPF
@PancreasVerona@EAHPBA@IHPBA@AnnSurgOncol
👉 In https://t.co/ZH8dQJtJBB 2 we now seek to investigate aspects contributing to FTR on a hospital and institutional level, across various Human Development Index countries, aiming to further improve patient care and safety in pancreatic surgery 🌏🌍🌎
🚨https://t.co/ogKjVuJEID 2
💡Survey on Hospital Factors Affecting Failure to Rescue in Pancreatic Surgery
Participate now!
👉https://t.co/wYFpvyqMut
✅ Complete the online Survey ⏰10min
✅ Stay anonymous
✅ No need for ethics approval
✅ PubMed citable co-authorship
What is the difference between long-term survival and cure following pancreatectomy for PDAC? Check this out: Cure Probabilities After Resection Of Pancreatic Ductal... : Annals of Surgery https://t.co/DLoU67eaGw @StefanoCrippa6@gimalleo@cuccoale@Aicep4@AISP_Pancreas
Today in @NatRevGastroHep, review BRPC-LAPC #PancreaticCancer
📌 Preoperative chemotherapy & radiation
📌 A-B-C (re)staging & surgical decision-making
📌Clinical research agenda
Great team effort 🇩🇪🇺🇸🇳🇱 https://t.co/220O76dUHp
Today a great @BJSurgery meeting and tomorrow is the World Pancreatic Cancer day 💜
😢 Pancreas surgery still associated to poor outcomes worldwide
🌍 In low human development index countries 🔺failure to rescue
🛟 Urgent measures needed!
🆓 access! https://t.co/mOWzT2nmDp